ZyVersa Therapeutics Q1 2024 Adj EPS $(4.53) Misses $(3.70) Estimate
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics (NASDAQ:ZVSA) reported a Q1 2024 adjusted EPS of $(4.53), missing the analyst consensus estimate of $(3.70) by 22.43%.
May 15, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ZyVersa Therapeutics reported a Q1 2024 adjusted EPS of $(4.53), significantly missing the analyst consensus estimate of $(3.70) by 22.43%.
The significant miss on the EPS estimate is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100